Results 51 to 60 of about 6,010 (179)
Pulmonary Circulation, Volume 16, Issue 3, July 2026.ABSTRACT Pulmonary arterial hypertension (PAH) is a rare and progressive disease characterized by remodeling of the pulmonary vasculature, which leads to increased pulmonary artery pressure and ultimately right ventricular failure. Although Japanese guidelines recommend combination therapy, real‐world data show inconsistencies in its implementation. We
Yoko Arai +4 more
wiley +1 more source
Inhaled Iloprost Versus Epoprostenol in Heart Transplant Recipients
, 2019 BACKGROUND: Acute right ventricular dysfunction is a challenging problem in the immediate postoperative period following orthotopic heart transplantation. There are no prior reports of the use of inhaled iloprost in the setting of acute right ventricular
Treggiari, Miriam M. +3 more
core +1 more source
Pulmonary Circulation, 2018 There are limited data investigating the epidemiology and resource utilization associated with parenteral prostacyclin use in children. We sought to examine national trends in treatment practices and resource utilization during prostacyclin initiation ...
Stephen A. Hart +2 more
doaj +1 more source
Pulmonary Circulation, Volume 16, Issue 3, July 2026.ABSTRACT Selection of therapy for pulmonary arterial hypertension (PAH) requires tradeoffs among disease severity, therapeutic benefit, adverse effects, treatment burden, quality of life, and patient values. Although professional societies endorse shared decision‐making (SDM) in this context, empirical data describing SDM in PAH are limited.
Paresh C. Giri +7 more
wiley +1 more source
Pulmonary Veno‐Occlusive Disease: A Focused Clinicopathologic Series
Pulmonary Circulation, Volume 16, Issue 3, July 2026.ABSTRACT Pulmonary veno‐occlusive disease (PVOD) is a rare and aggressive subtype of pulmonary arterial hypertension characterized by fibroproliferative obstruction of post‐capillary pulmonary venules leading to increased pulmonary vascular resistance and progressive right ventricular failure.
Yub Raj Sedhai +12 more
wiley +1 more source
Evidence for PDZ‐Binding Kinase in Lung Disease With an Emphasis on PAH
Pulmonary Circulation, Volume 16, Issue 3, July 2026.ABSTRACT Originally named T‐cell‐originated Lymphokine‐activated killer protein kinase (TOPK), PDZ‐Binding Kinase (PBK) is a serine/threonine kinase that is a member of the family of mitogen‐activated protein kinases (MAPKKs), which is overexpressed in lung cancer and interstitial pulmonary fibrosis (IPF). Along these lines, recent work also shows that
Scott A. Barman +2 more
wiley +1 more source
Goiter in a Patient with Pulmonary Arterial Hypertension Treated with Epoprostenol
Case Reports in Pulmonology, 2020 A 35-year-old female with pulmonary arterial hypertension (PAH) who presented with complaints of progressively worsening dysphagia, facial swelling, and shortness of breath, was found to have a large goiter. In patients treated with epoprostenol for long
Shaadi Abughazaleh, Zeenat Safdar
doaj +1 more source
Cumulative epoprostenol dose for each patient.
, 2015 Bars show the cumulative dose of epoprostenol per body weight within the initial 180 days. The blue and red bars describe each patient’s cumulative dose in the slow- and rapid-initiation groups, respectively.
Mai Kimura (717505) +7 more
core +1 more source
Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension
, 2020 Sarcoidosis-Associated Pulmonary Hypertension (SAPH) is a common finding in patients with chronic sarcoidosis and is associated with increased mortality.
Farber, Harrison +5 more
core +1 more source
, 2007 Intravenous epoprostenol improves exercise capacity and survival in patients with pulmonary arterial hypertension (PAH); however, chemical instability and a short half-life have caused limitations in its use.
Paillette LD +11 more
core +1 more source